The FDA's two-speed problem: a $70M gene therapy for one girl, and a 25-patient-an-hour telehealth line

Two STAT investigations published within eleven days of each other expose a single regulatory gap. The FDA is being asked to approve a one-patient gene therapy for a disease so rare that its sponsor cannot afford the trial the agency wants. It is also being asked to police a Novo Nordisk-endorsed telehealth line that former employees say clears 25 weight-loss patients an hour.

Matt Wilsey has spent about a decade and roughly $70 million of his own money trying to develop a treatment for his daughter Grace, who has NGLY1 deficiency, a genetic condition that has prevented her from speaking or walking with ease. Wilsey's company, Grace Science, has now dosed 10 patients with a gene-therapy candidate, including Grace. Three weeks before the scene described in STAT's July 9 feature, she received the therapy and was hospitalized again, feebler than before. The trial is out of money and still does not have what the FDA says it needs for approval. Wilsey is pressing the agency anyway, which STAT calls a pivotal test case for ultra-rare disease development.

The "ultra-rare" label describes conditions so uncommon that standard commercial drug development math does not work: no company can recoup a $70 million trial from a few dozen patients. The FDA's ultra-rare pathway is meant to bend the usual approval requirements, but it does not waive them. Grace Science's failure mode is financial, not scientific. It has produced a candidate the family believes works, and it cannot afford the trial design the regulator wants.

The same agency runs a much looser gate at the other end of the market. GLP-1 agonists are a class of obesity and diabetes drugs whose demand has outrun the legitimate supply chain. Compounded and telehealth versions have filled the gap. STAT's July 20 investigation names LifeMD, a telehealth company that appears on Novo Nordisk's own NovoCare provider directory as offering "legitimate medicine sourcing and patient support" for people seeking the drugs. Five former employees and two lawsuits from former top leaders allege providers were expected to review roughly two minutes per case and were discouraged from asking medically relevant questions because that would "delay care." LifeMD strenuously denies the allegations.

The Novo Nordisk listing ties the drugmaker to the telehealth firm. Its own patient-support directory elevates a company former employees accuse of prescription-volume-driven care. Novo Nordisk has not, in the open record, withdrawn the listing.

A separate academic study gives the second thread independent corroboration. A JAMA secret-shopper study covered by STAT on July 6 found that GLP-1 prescriptions from telehealth sites are not often backed by appropriate clinical care.

The two threads share a single institutional gap. The FDA's ultra-rare pathway is built to be slow, deliberate, and statistically rigorous. For Grace Science, the rigor is unaffordable. The agency's mass-prescription oversight was not designed for a market in which millions of patients seek weight-loss drugs through brief telehealth encounters, and the agency has not retrofitted the rule.

Neither posture will bend easily. STAT calls Wilsey's public pressure on the FDA a test case for the ultra-rare pathway; a softening for one patient would be a precedent the agency does not want. The LifeMD allegations run through private litigation and a denial, and the NovoCare listing will not move until the drugmaker or its regulator does. STAT's Readout LOUD podcast on July 23 bundled the two threads. The episode added no new facts.

Both failures sit on the same regulator. One patient is named. The other queue runs in the millions.